News - Cardio-vascular, Financial

Filter

Current filters:

Cardio-vascularFinancial

Popular Filters

1 to 25 of 31 results

Boehringer Ingelheim aims for clean slate with $650 million Pradaxa settlement, says analyst

Boehringer Ingelheim aims for clean slate with $650 million Pradaxa settlement, says analyst

02-06-2014

After facing more than 2,000 law suits in the USA, claiming Pradaxa (dabigatran) caused severe or fatal…

Boehringer IngelheimCardio-vascularFinancialLegalPharmaceutical

Boehringer Ingelheim agrees $650 million comprehensive settlement of US Pradaxa litigation

Boehringer Ingelheim agrees $650 million comprehensive settlement of US Pradaxa litigation

28-05-2014

German family-owned pharma major Boehringer Ingelheim says it has reached a comprehensive settlement…

Boehringer IngelheimCardio-vascularFinancialLegalPharmaceuticalPradaxaUSA

Ligand licenses five programs to Viking Therapeutics

23-05-2014

US drugmaker Ligand Pharmaceuticals has out-licensed rights to five programs to Viking Therapeutics,…

Cardio-vascularDiabetesFinancialLicensingLigand PharmaceuticalsMetabolicsPharmaceuticalViking Therapeutics

Heart Metabolics raises $20 million for Phase III heart disease drug trial

17-04-2014

Irish biotech company Heart Metabolics has completed a $20 million round of financing to support its…

BiotechnologyCardio-metabolic diseasesCardio-vascularDrug discoveryFinancialHeart diseaseHeart Metabolics LimitedIrelandPeter Milner

Servier Canada collaborates in two research projects

Servier Canada collaborates in two research projects

17-02-2014

Two major projects in clinical research conducted by Canada’s Montreal Heart Institute (MHI) and the…

CanadaCardio-vascularFinancialNorth AmericaPharmaceuticalResearchServier

Catalyst-rich period ahead for key trial results from BioLineRx

09-12-2013

Israeli drug developer BioLineRx is entering a catalyst-rich phase over the next 12 months, which will…

Anti-viralsBioLineRxBL-1040BL-8020BL-8040Cardio-vascularFinancialOncologyPharmaceuticalResearch

Amarin cuts 50% of staff after negative FDA decision

23-10-2013

Amarin has announced plans to cut 50% of its staff worldwide after the recent US Food and Drug Administration…

AmarinCardio-vascularFinancialManagementNorth AmericaPharmaceuticalVascepa

Actelion’s PAH drugs boost 4% rise in sales

Actelion’s PAH drugs boost 4% rise in sales

17-10-2013

Actelion has announced its financial results for the first nine months of 2013 revealing product sales…

ActelionBiotechnologyCardio-vascularCeptaris TherapeuticsEuropeFinancialTracleerVeletriVentavisZavesca

Sanofi strengthens its presence in Algeria with €70 million investment

Sanofi strengthens its presence in Algeria with €70 million investment

26-09-2013

French drug major Sanofi revealed today that construction has begun on its new Sidi Abdellah industrial…

Cardio-vascularDiabetesFinancialPharmaceuticalProductionRest of the WorldSanofi

Cytomedix reorganizes R&D to cut cash burn

18-09-2013

US biotechnology company Cytomedix (OTCQX: CMXI) will reorganize its R&D activities to reduce cash burn.…

BiotechnologyCardio-vascularCytomedixFinancialNorth America

Ireland's HSE announces preferred ACE inhibitor and ARBs

06-09-2013

Ireland Health Service Executive's (HSE) Medicines Management Program (MMP) has identified two new preferred…

Cardio-vascularEuropeFinancialGenericsPricing

Statin drugs save health care systems money as well as saving lives, UK study shows

11-07-2013

Statins not only help save lives but are great value for money too, even in lower risk patients, according…

Cardio-vascularEuropeFinancialGenericsHealthcarePharmaceutical

Trevena and Forest Labs collaborate on TRV027 for acute heart failure

10-05-2013

US GPCR ligand drug developer Trevena and Forest Laboratories (NYSE: FRX) have entered into a collaborative…

Cardio-vascularFinancialForest LaboratoriesLicensingPharmaceuticalTrevenaTRV027

Merck & Co opens new $120 million manufacturing plant in China

19-04-2013

US Pharma giant Merck & Co (NYSE: MRK) has opened its new pharmaceutical manufacturing facility in Hangzhou,…

Asia-PacificCardio-vascularDiabetesFinancialMerck & CoPharmaceuticalProductionRespiratory and Pulmonary

Adherence to generic cholesterol-lowering drugs linked to fall in total care costs

04-04-2013

People who regularly take statins to reduce high cholesterol will see lower hospitalization rates according…

Cardio-vascularFinancialGenericsMarkets & MarketingNorth America

Proposal to list AstraZeneca's Brilinta in New Zealand

26-03-2013

New Zealand's Pharmaceutical Management Agency, PHARMAC, is seeking feedback on a proposal to fund the…

Asia-PacificAstraZenecaBrilintaCardio-vascularFinancialHealthcarePharmaceuticalPricingticagrelor

New Zealand consults on amiloride, perindopril and trandolapril funding

11-03-2013

New Zealand's Pharmaceutical Management Agency, PHARMAC, is seeking feedback on a proposal to fund new…

amilorideApotexAsia-PacificCardio-vascularFinancialGenericsHealthcareperindopriltrandolapril

Chelsea Thera to re-file Northera NDA with existing data; Celgene share buyback

21-02-2013

Chelsea Therapeutics International (Nasdaq: CHTP) saw its shares more than double to $1.61 in pre-market…

BiotechnologyCardio-vascularCelgeneChelsea TherapeuticsFinancialNorth AmericaNortheraRegulation

Financing for Life Sciences Entrepreneurs antiplatelet candidate NmC; and Ambit's AML drug

06-11-2012

Life Science Entrepreneurs, a Spanish company dedicated to the early-stage development of high-risk/very…

Ambit BiosciencesCardio-vascularFinancialLife Sciences EntrepreneursNmCOncologyPharmaceuticalquizartinibResearch

Isis earns $25 million milestone from Genzyme as US FDA accepts Kynamro NDA

31-05-2012

The US Food and Drug Administration has accepted for filing the New Drug Application for Kynamro (mipomersen…

BiotechnologyCardio-vascularFinancialGenzymeIsis PharmaceuticalsKynamroNorth AmericaPharmaceuticalRegulationSanofi

Mylan starts selling generic Lipitor in Europe; to buy back shares

14-05-2012

US generic drug major Mylan's (Nasdaq: MYL) shares 2.2% to $21.55 in morning last Friday after the company…

atorvastatinCardio-vascularEuropeFinancialGenericsLipitorMarkets & MarketingMylan Laboratories

1 to 25 of 31 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top